Fulgent Genetics, Inc. (FLGT) intrinsic value & 10-year financials
Fulgent Genetics, Inc. (FLGT) has a Graham intrinsic value of $153.83 per share. At $19.81 on Oct 17, 2026, the stock trades 87% below that value. Over the last 10 fiscal years revenue grew 37.6% a year to $322.7M, with an average return on invested capital of 11.5%.
- Graham intrinsic value
- $153.83
- Share price (Oct 17, 2026)
- $19.81
- Price vs Graham value
- 87% below
- Market cap
- $609.7M
- Revenue (FY2025)
- $322.7M
- Revenue growth (10-yr CAGR)
- 37.6%
- ROIC (10-yr avg)
- 11.5%
- Free cash flow (FY2025)
- -$124.2M
FLGT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $322.7M | -$60.5M | — | -$124.2M | -28.2% | -7.4% |
| FY2024 | $283.5M | -$42.7M | — | -$19.3M | -26.1% | -5.8% |
| FY2023 | $289.2M | -$167.8M | — | $4.8M | -67.6% | -17.4% |
| FY2022 | $619.0M | $143.4M | — | $234.7M | 28.8% | 12.6% |
| FY2021 | $992.6M | $507.4M | — | $514.8M | 68.1% | 67.8% |
| FY2020 | $421.7M | $214.3M | — | $105.5M | 68.8% | 78.0% |
| FY2019 | $32.5M | -$411.0K | — | $4.3M | -1.3% | -0.6% |
| FY2018 | $21.4M | -$5.6M | — | -$3.0M | -23.7% | -9.6% |
| FY2017 | $18.7M | -$2.5M | — | -$1.6M | -18.6% | -4.6% |
| FY2016 | $18.3M | -$5.3M | — | $617.0K | 5.0% | 1.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Fulgent Genetics, Inc. is a consistent compounder, expanding top-line revenue at 37.6% annually over the past decade.
Fulgent Genetics, Inc. returns on capital have been average, hovering around 11.5% ROIC over the decade.
Fulgent Genetics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Fulgent Genetics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $153.83 per share.